Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 8 October 2025 - 9 October 2025

Costco Stock Surges Amid Retail Gloom – Will $900+ Shares Keep Climbing?

Costco Stock Soars Amid Retail Gloom – What’s Driving the Rally and Will It Last?

Stock Price & Recent Performance Costco’s stock has been on a long-term upward climb, and 2025 is no exception – though it hasn’t been a smooth ride. After a strong rally in the first half of the year, Costco (COST) shares reached an intraday record high around $1,078earlier in 2025ts2.tech. Enthusiasm was fueled by robust sales growth and a broader market rally. However, by late summer the stock had pulled back into the mid-$900s amid some profit-taking and market volatilityts2.tech. As of October 9, 2025, COST trades in the $914–$928 rangets2.tech – essentially back to where it started the year (roughly flat year-to-date
9 October 2025
····
CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

Company Background & Business Model Cipher Mining is a pure-play Bitcoin miner that specializes in large-scale, energy-efficient data-center mining ts2.tech. It locates facilities “behind the meter” at low-cost renewable power sites in West Texas ts2.tech. Its flagship “Black Pearl” complex (Odessa, TX) is a 150 MW facility serving both Bitcoin mining and high-performance computing (HPC) ts2.tech. As of mid-2025, Cipher had deployed ~16.8 EH/s of mining capacity (with next-gen ASIC miners) ts2.tech and plans to reach ~23.5 EH/s by Q3’25 ts2.tech. To fund growth, it has a large 2.6 GW pipeline of additional power projects ts2.tech. In Q2’25 Cipher produced ~150 BTC and achieved $44 M
9 October 2025
····
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015renaissancecapital.com. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listingstockanalysis.com. Turn’s mission is to “turn the tides” in medicine by developing technologies that heal, not just manage, challenging traditional treatmentsbenzinga.com. CEO Bradley Burnam (the founder) leads a lean operation “built on a shoestring, with an absolute disdain for waste,” as he emphasized during the Nasdaq bell-ringing ceremonybenzinga.com. Burnam and his team bring a “patient-first” approach and a frugal business model to drug development, aiming to maximize R&D output
9 October 2025
····
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to
9 October 2025
···
PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

Key Data & Metrics (as of October 9, 2025) Metric Value Stock Price (Oct 8, 2025) $138.84 (close)marketbeat.comDown ~6% in past month; ~–6% YTDfinviz.comindexbox.io 52-Week Range Low $127.60 – High $177.48markets.businessinsider.com Market Capitalization ~$193 Billionmarkets.businessinsider.com Forward P/E (2025E) ~17.5× (near industry avg ~17.5×)finviz.com Trailing P/E (TTM) ~21.8×markets.businessinsider.com PEG Ratio (Forward) ~3.5 (industry ~2.3)finviz.com Annual Dividend $5.69 per share (yield ~4.0%)macrotrends.net Dividend Growth 53 years consecutive increases (5% hike in 2025)pepsico.com Q3 2025 Revenue $23.94 B (+2.6% YoY)investing.com Q3 2025 Adjusted EPS $2.29 (beat est. $2.26; –1.7% YoY)investing.comfinviz.com 2025 Full-Year Forecast Low-single-digit organic rev growth; Core EPS ~flat YoYinvesting.com Analyst Consensus Hold (21
9 October 2025
····
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s Strong Quarter Signals a Turnaround Tilray Brands kicked off its fiscal 2026 with better-than-expected results, signaling that aggressive cost-cutting and diversification efforts are bearing fruit. The company’s Q1 FY2026 revenue hit $209.5 million, a 5% increase over last year’s quarter stocktitan.net. More impressively, Tilray managed to swing to a net profit of $1.5 million (or $0.00 per share) – a stark improvement from the -$34.7 million loss in the prior-year period stocktitan.net stocktitan.net. This marks one of Tilray’s first profitable quarters since its 2018 IPO, a milestone achieved through tighter operational discipline. Adjusted EBITDA came in at $10.2 million
9 October 2025
····
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Stock Price Surge: From IPO to Record Highs Tempus AI’s stock has been on a remarkable tear since its mid-2024 IPO. The Chicago-based healthtech firm – founded in 2015 by Eric Lefkofsky (of Groupon fame) – went public in June 2024 at around $21 per share, and the price has since quadrupled ts2.tech. After a steady climb through 2024, momentum accelerated in 2025 as the company delivered strong results and AI breakthroughs. By early September 2025, TEM had more than doubled its IPO price, reaching the high-$80s to $90 range ts2.tech. A series of catalysts (detailed below) then propelled the
9 October 2025
···
UiPath’s Automation Stock Soars on AI Buzz – Latest PATH Analysis & Outlook

UiPath’s Automation Stock Soars on AI Buzz – Latest PATH Analysis & Outlook

Stock Performance: Hitting New Highs on AI Momentum UiPath’s stock has been on a tear in early October 2025, propelled by excitement around artificial intelligence. On October 8, PATH jumped 5.13% to close at $15.58 – its highest closing price since May 2024stocktwits.com. This capped a rapid climb from the ~$12–13 range just a week earlier. In fact, shares gapped up in late September after the company’s AI announcements, breaking out of a long trading range. The surge continued into this week, with PATH notching a new 52-week intraday high and then rising further in post-market trading (up over 7% after hours on
9 October 2025
···
CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

Sources: Official company reports and press releases; Yahoo Finance and Zacks Investment Research; Reuters and CNBC interviews; TS2 Tech stock analysis and cybersecurity newsts2.technasdaq.commarkets.financialcontent.commarketbeat.comts2.techsiliconangle.comts2.tech. These provide the latest financial data, expert commentary, and industry context as of October 8, 2025.
8 October 2025
····
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million sharesindmoney.com. Fintel’s data as of 7 Oct 2025 list a market cap of roughly $6.2 billion, a beta of 1.32 and a short interest of 26.3 %, suggesting significant volatility and short‑seller interestfintel.io. The average one‑year price target of $81.3 implies modest
8 October 2025
···
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)
8 October 2025
···
Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s Business Model & Market Position Cisco Systems is best known as the world’s largest vendor of networking hardware and software, powering much of the internet’s infrastructure. The company’s business model centers on selling network equipment (like routers, switches, and wireless access points), along with security solutions, collaboration tools (e.g. Webex conferencing gear/software), and observability software (monitoring and analytics, bolstered by its 2024 acquisition of Splunk). In addition, Cisco provides a range of services – from technical support and maintenance contracts to cloud-managed software subscriptions. Cisco generates revenue both through direct sales and via a global channel of resellers and distributors, ensuring its products reach enterprises of all sizes and governments worldwidenasdaq.com. This
8 October 2025
···
1 … 277 278 279 280 281 282

Stock Market Today

Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
SYDNEY, Feb 7, 2026, 17:41 AEDT — Market closed Wesfarmers shares ended Friday down 1.33% at A$85.04, trimming a sharp gain a day earlier as the Australian market slid into the weekend. (wesfarmers.com.au) Why it matters now is timing. Australia’s reporting season is starting to bite, and Wesfarmers’ half-year results are due on Feb. 19, a date investors have been circling as they look for a read on household demand and margins across the group. (wesfarmers.com.au) The broader tape has not been calm. A week of heavy moves in commodities and tech has pushed investors to cut exposure to cyclical
Go toTop